

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

| Department | Project Number | Project Title | Principal Investigator | Source of Funding | 22-23 Receipts |
|------------|----------------|--|------------------------|-----------------------------|----------------|
| Neurology | 63867 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201) | Dr Naritoku, D | Xenon Pharmaceuticals, Inc. | |

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2022 - September 30, 2023

| Department | Project Number | Project Title | Principal Investigator | Source of Funding | 22-23 Receipts |
|------------|----------------|--|------------------------|-------------------|----------------|
| OB-GYN | 63887 | A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to EvaluateThe Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy | | | |

South Alabama Medical Science Foundation
 Cash Receipts (For Projects Over \$2,000)
 October 1, 2022 - September 30, 2023

| Department | Project Number | Project Title | Principal Investigator | Source of Funding | 22-23 Receipts |
|------------|----------------|--|------------------------|---------------------------|----------------|
| Surgery | 63879 | Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21) | Dr Bright, A | Mediwound | 6,128.52 |
| (e)7-33810 | 33810 | The CALIBER Study: Randomized Controlled Trial of LINX versus Double-Dose Pump Inhibitor Therapy in the Treatment of Gastroesophageal Reflux Disease (TRX_2018_01) | (b)7-33810 (o)7-33810 | Ethicon Endo-Surgery, Inc | 252.00 |

South Alabama Medical Science Foundation
 Cash Receipts (For Projects Over \$2,000)
 October 1, 2022 - September 30, 2023

| Department | Project Number | Project Title | Principal Investigator | Source of Funding | 22-23 Receipts |
|------------|----------------|---------------------------------------|------------------------|----------------------|--------------------------|
| | 62648 | Royalty On Sales of Antibody Products | Dr Scammell, J | QED Bioscience | 3,457.60 |
| | | | | Total Other Research | <u>3,457.60</u> |
| | | | | Total | <u><u>325,252.25</u></u> |